MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Regeneron Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

608.74 -2.67

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

608

Max

625.5

Schlüsselkennzahlen

By Trading Economics

Einkommen

-423M

918M

Verkäufe

69M

3.8B

KGV

Branchendurchschnitt

16.529

63.778

EPS

12.07

Dividendenrendite

0.56

Gewinnspanne

24.219

Angestellte

15,106

EBITDA

-534M

1.1B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+51.62% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.56%

2.39%

Nächstes Ergebnis

29. Apr. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-5B

70B

Vorheriger Eröffnungskurs

611.41

Vorheriger Schlusskurs

608.74

Nachrichtenstimmung

By Acuity

37%

63%

122 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Regeneron Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Feb. 2025, 12:13 UTC

Ergebnisse

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

8. Juli 2024, 12:00 UTC

Ergebnisse

Regeneron Expects Earnings Hit After $24 Million R&D Charge

28. Feb. 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4. Feb. 2025, 11:58 UTC

Ergebnisse

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4. Feb. 2025, 11:37 UTC

Ergebnisse

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4. Feb. 2025, 11:37 UTC

Ergebnisse

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4. Feb. 2025, 11:36 UTC

Ergebnisse

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4. Feb. 2025, 11:35 UTC

Ergebnisse

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

4. Feb. 2025, 11:35 UTC

Ergebnisse

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

4. Feb. 2025, 11:34 UTC

Ergebnisse

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

4. Feb. 2025, 11:34 UTC

Ergebnisse

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

4. Feb. 2025, 11:32 UTC

Ergebnisse

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

4. Feb. 2025, 11:31 UTC

Ergebnisse

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

31. Jan. 2025, 08:30 UTC

Akquisitionen, Fusionen, Übernahmen

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

28. Jan. 2025, 10:30 UTC

Top News

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

31. Okt. 2024, 13:58 UTC

Ergebnisse

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

31. Okt. 2024, 10:52 UTC

Ergebnisse

Regeneron Earnings Top Views For Biotech Giant -- IBD

31. Okt. 2024, 10:34 UTC

Ergebnisse

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

31. Okt. 2024, 10:33 UTC

Ergebnisse

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

31. Okt. 2024, 10:33 UTC

Ergebnisse

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

31. Okt. 2024, 10:32 UTC

Ergebnisse

Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 23% to $3.82B >REGN

31. Okt. 2024, 10:30 UTC

Ergebnisse

Regeneron Pharma 3Q Rev $3.72B >REGN

31. Okt. 2024, 10:30 UTC

Ergebnisse

Regeneron Pharma 3Q EPS $11.54 >REGN

31. Okt. 2024, 10:30 UTC

Ergebnisse

Regeneron Pharma 3Q Net $1.34B >REGN

25. Okt. 2024, 20:25 UTC

Ergebnisse

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

1. Aug. 2024, 11:50 UTC

Ergebnisse

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1. Aug. 2024, 10:37 UTC

Ergebnisse

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1. Aug. 2024, 10:30 UTC

Ergebnisse

Regeneron Pharma 2Q EPS $12.41 >REGN

1. Aug. 2024, 10:30 UTC

Ergebnisse

Regeneron Pharma 2Q Net $1.43B >REGN

1. Aug. 2024, 10:30 UTC

Ergebnisse

Regeneron Pharma 2Q Rev $3.55B >REGN

Peer-Vergleich

Kursveränderung

Regeneron Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

51.62% Vorteil

12-Monats-Prognose

Durchschnitt 948.55 USD  51.62%

Hoch 1,182 USD

Tief 575 USD

Basierend auf 20 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Regeneron Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

20 ratings

16

Buy

3

Halten

1

Sell

Technischer Score

By Trading Central

610.1001 / 662.33Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

122 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.